Skip to Content


Treatment for Alpha-1 Proteinase Inhibitor Deficiency

Update: Glassia (alpha1-proteinase inhibitor (human)) Now FDA Approved - July 1, 2010

BLA Submitted for AAT-IV

Kamada Submits U.S. Biologics License Application for the First Liquid, Ready to Use AAT for the Treatment of Alpha-1 Antitrypsin Deficiency

NESS ZIONA, Israel--(BUSINESS WIRE)--Jun 2, 2009 - Kamada (TASE:KMDA) – a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced that it has submitted a Biologics License Application ("BLA") to the U.S. Food and Drug Administration ("FDA") for its lead clinical candidate, intravenous alpha-1 antitrypsin ("AAT-IV"), for the treatment of Alpha-1 Antitrypsin Deficiency.

David Tsur, Chief Executive Officer of Kamada, said, "The submission of our AAT-IV BLA is an important milestone for Kamada, as it positions us one step closer to bringing our product to the US and European markets. We believe that the data supporting the BLA for our innovative AAT-IV are strong and we look forward to working with the FDA to bring this important and advantageous therapy to market for the benefit of the patient population."

About Kamada's IV-AAT

Kamada has developed a unique, high purity, liquid, ready-to-use human plasma derived AAT indicated for the treatment of Alpha 1 Deficiency. The product is produced using a sophisticated, chromatographic purification method.

About Kamada

Kamada is a public biopharmaceutical company (TASE:KMDA) developing, producing and marketing a line of specialty life-saving biopharmaceuticals. Licensed and marketed worldwide, several of these specialty therapeutics are currently undergoing advanced clinical trials. Additional information is available at

Contact: Kamada
David Tsur, CEO, +972-8-940-6472
The Trout Group LLC
Marcy Nanus, +1-646-378-2927 or +1-516-901-2584 (cell)

Posted: June 2009

Related Articles

Glassia (alpha1-proteinase inhibitor (human)) FDA Approval History

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.